Ceritinib Rare Indications Study in ALK+ Tumors

Inclusion Criteria:

* Patient has a histologically or cytologically confirmed diagnosis of ALK positive (ALK+) tumor other than Non-Small Cell Lung Cancer (NSCLC).
* Patient must provide an archival or fresh tumor tissue before the first dose of the study drug for ALK testing at a Novartis designated central laboratory.
* Patient has WHO Performance Status (PS) ≤ 2
* Patient must have received at least one line of prior systemic treatment for recurrent, locally advanced and/or metastatic disease, and may have discontinued for:

  * Disease progression as defined by RECIST 1.1 for solid tumors; by RANO for GBM and by Cheson assessment criteria for lymphoma, or
  * Intolerance described as any discontinuation due to an AE of any grade despite appropriate supportive treatment
* Patient has at least one measurable lesion as defined by appropriate guidelines. A lesion at a previously irradiated site may only be counted as a target lesion if there is clear sign of progression since the irradiation.
* Patient has received no chemotherapy, immunotherapy or stem cell therapy at least 4 weeks before starting ceritinib
* Radiotherapy and prior ALK inhibitors must be stopped at least 1 week prior to starting ceritinib
* Recovered from all toxicities related to prior anticancer therapies to grade ≤ 1 (Common Terminology Criteria for Adverse Events \[CTCAE\] v4.03).

Exclusion Criteria:

* Patient has ALK+lung cancer
* Patient with symptomatic CNS metastases who are neurologically unstable or have required increasing doses of steroids within the 2 weeks prior to study entry to manage CNS symptoms.
* Patient with acute or chronic GI disease that may significantly alter the absorption of ceritinib.
* Patient with a history of pancreatitis or history of increased amylase or lipase that was due to pancreatic disease.
* Patient has history of interstitial lung disease or interstitial pneumonitis, including clinically significant radiation pneumonitis.
* Patient has clinically significant, uncontrolled heart disease and/or recent cardiac event (within 6 months).
* Patient has evidence of active viral hepatitis, including Hepatitis A, B or C (testing for viral hepatitis is not mandatory).
* Patient has known diagnosis of human immunodeficiency virus (HIV) infection (HIV testing is not mandatory).